Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.66
-0.33 (-4.72%)
At close: Aug 28, 2026, 4:00 PM EDT
6.65
-0.01 (-0.15%)
After-hours: Aug 28, 2026, 7:52 PM EDT
Nuvation Bio Employees
Nuvation Bio had 305 employees as of June 30, 2026. The number of employees increased by 27 or 9.71% compared to the same quarter last year.
Employees
305
Change
27
Growth
9.71%
Revenue / Employee
$557,049
Profits / Employee
-$491,236
Market Cap
2.34B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 305 | 27 | 9.71% |
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Maravai LifeSciences Holdings | 415 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 274 |
| Pharvaris | 148 |
| Kodiak Sciences | 141 |
| Rapport Therapeutics | 84 |
NUVB News
- 7 days ago - Nuvation Bio initiated with an Overweight at Cantor Fitzgerald - TheFly
- 8 days ago - Nuvation Bio granted FDA Fast Track Designation for safusidenib in glioma - TheFly
- 8 days ago - Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - PRNewsWire
- 10 days ago - Nuvation Bio initiated with an Overweight at JPMorgan - TheFly
- 21 days ago - Nuvation Bio price target raised to $14 from $12 at B. Riley - TheFly
- 21 days ago - Nuvation Bio price target raised to $20 from $19 at RBC Capital - TheFly
- 22 days ago - Nuvation Bio Slides: Corporate presentation - Filings
- 22 days ago - Nuvation Bio Earnings Call Transcript: Q2 2026 - Transcripts